Standard BioTools (LAB) Advances Treeline Merger With Asset Divestiture and Cash Inflow

• Standard BioTools (LAB) has agreed to sell its Mass Cytometry business to Multiplex Bio, a new entity led by industry veterans, to streamline operations ahead of its pending merger with Treeline.
• The company also received approximately $30 million from Illumina to buy out the 2026 earnout and future royalty rights tied to the SomaLogic business, boosting pro forma net cash for the merger.
• The U.S. Federal Trade Commission has granted early termination of the waiting period for the Treeline merger, with both the divestiture and merger expected to close by the end of 2026.

Standard BioTools Inc. (NASDAQ: LAB) is executing a strategic portfolio realignment to facilitate its pending all-stock merger with Treeline Biosciences. The biotechnology firm has announced the sale of its non-core Mass Cytometry business to Multiplex Bio, a newly formed entity . This divestiture is designed to exit operations that do not align with the combined entity's focus on drug discovery platforms .

Simultaneously, Standard BioTools has secured a significant cash infusion from Illumina Inc. The company received approximately $30 million to terminate the 2026 earnout and all future royalty payments related to Illumina’s earlier acquisition of the SomaLogic business . This payment directly increases the company's pro forma net cash position, which will positively impact the exchange ratio calculation for Treeline shareholders .

What are the terms of the Mass Cytometry sale to Multiplex Bio?

The divestiture involves the sale of the CyTOF and Hyperion product lines to Multiplex Bio. The transaction is valued at up to $10 million, structured through a seller’s note and potential milestone payments . Standard BioTools will also provide a working capital loan of up to $10 million to support the transition if third-party financing is unavailable .

Multiplex Bio is led by Michael Johnson, Tom Villani, and Charles Coffman, who previously co-founded Visikol. The entity plans to maintain continuity of customer relationships and the majority of the mass cytometry team . Products will continue to be commercialized under the Standard BioTools brand to ensure stability for researchers relying on these spatial biology tools .

How does the Illumina buyout impact the Treeline merger?

The $30 million settlement with Illumina eliminates complex contingent liabilities and intellectual property obligations. By waiving future payments, Standard BioTools has accelerated value realization and simplified its balance sheet . This cash inflow is critical for tightening the financial contours of the upcoming merger for shareholders .

The U.S. Federal Trade Commission has already terminated the waiting period for the Treeline merger under the Hart-Scott-Rodino Antitrust Improvements Act. This regulatory clearance removes a major hurdle for the transaction, which is now subject only to stockholder approval .

What is the current financial outlook for Standard BioTools?

Standard BioTools is scheduled to report Q2 2026 earnings after market close on August 5, 2026. Analyst consensus projects a loss of $0.01 per share with revenue estimated at approximately $20.8 million . The stock has shown volatility, trading up 2.7% to $0.82 prior to the announcement .

Institutional activity has been notable, with Russell Investments Group Ltd. increasing its stake by nearly 3,000% in the third quarter. However, analysts currently rate the stock as a Hold, citing deteriorating financial performance including sharp revenue declines and ongoing negative free cash flow . Historical data shows significant variance between estimates and reported figures, with Q2 2025 revenue missing estimates by 45%.

Both the Mass Cytometry sale and the Treeline merger are expected to close by the end of 2026. These strategic moves are intended to consolidate resources around the combined Treeline entity, which focuses on advanced drug discovery platforms . The company aims to reduce balance sheet complexity and improve operational focus in a competitive biotechnology landscape .